News for SpringWorks Therapeutics Inc Stock (SWTX)

SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023

GlobeNewsWire • 04/17/23

BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023

Business Wire • 04/17/23

MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023

GlobeNewsWire • 04/17/23

MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023

Business Wire • 04/17/23

SpringWorks Therapeutics: Pfizer Offshoot With Interesting Pipeline

Seeking Alpha • 04/14/23

Get In Now. 7 Stocks That Are Set to Soar.

InvestorPlace • 04/13/23

SpringWorks Therapeutics Announces New England Journal of Medicine Publication of Phase 3 DeFi Trial Evaluating Nirogacestat in Adults with Desmoid Tumors

GlobeNewsWire • 03/08/23

SpringWorks Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference

GlobeNewsWire • 03/01/23

SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights

GlobeNewsWire • 02/28/23

SpringWorks Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Nirogacestat for the Treatment of Adults with Desmoid Tumors

GlobeNewsWire • 02/27/23

SpringWorks Therapeutics Highlights 2022 Accomplishments and Anticipated Milestones for 2023 at the 41st Annual J.P. Morgan Healthcare Conference

GlobeNewsWire • 01/09/23

Kaskela Law LLC Announces Investigation of SpringWorks Therapeutics, Inc. (SWTX) and Encourages Long-Term SWTX Investors to Contact the Firm

Newsfile Corp • 01/06/23

SpringWorks Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

GlobeNewsWire • 01/03/23

SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Nirogacestat for the Treatment of Adults with Desmoid Tumors

GlobeNewsWire • 12/27/22

SpringWorks Therapeutics to Participate in the Evercore ISI 5th Annual HealthCONx Conference

GlobeNewsWire • 11/22/22

SpringWorks Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

GlobeNewsWire • 11/03/22

Applied BioMath, LLC Announces Collaboration with SpringWorks Therapeutics, Inc. for Systems Pharmacology Modeling in Multiple Myeloma

PRNewsWire • 11/01/22

Wall Street Analysts Think SpringWorks Therapeutics (SWTX) Could Surge 212%: Read This Before Placing a Bet

Zacks Investment Research • 10/19/22

SpringWorks Therapeutics Announces Dosing of First Patient in Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors

GlobeNewsWire • 09/29/22

SpringWorks (SWTX), GSK Expand Deal to Treat Multiple Myeloma

Zacks Investment Research • 09/08/22

SpringWorks Therapeutics Announces $225 Million Private Placement Financing

GlobeNewsWire • 09/07/22

SpringWorks Announces Expansion of Global, Non-Exclusive Collaboration with GSK for Nirogacestat in Combination with Blenrep in Patients with Multiple Myeloma

GlobeNewsWire • 09/07/22

SpringWorks Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

GlobeNewsWire • 08/04/22

SpringWorks Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare Conference

GlobeNewsWire • 08/02/22

SpringWorks Therapeutics Appoints Carlos Albán to its Board of Directors

GlobeNewsWire • 07/15/22